For the Inventor, By the Inventor

Enter assignee name

Erytech Pharma

USPTO Granted Patents = 18

CIPO Patents = 5

EPO Patents = 12

Trademarks = 2

Forward Citations = 137

Loading Chart...

Loading Chart...

17 inventors (with patents filed for the assignee):

Yann Godfrin (15 out of 17 patents)

Fabien Gay (4 out of 4 patents)

Vanessa Bourgeaux (4 out of 4 patents)

4. Thomas Cortese (3 out of 3 patents)

5. Alice Banz (3 out of 3 patents)

6. Hélène Blois (2 out of 8 patents)

7. Pierre-Olivier Goineau (2 out of 2 patents)

8. Emmanuelle Dufour (1 out of 1 patent)

9. Manuel Blanc (1 out of 1 patent)

10. Aurélien Meyzaud (1 out of 1 patent)

11. Karine Aguera (1 out of 1 patent)

12. Willy Berlier (1 out of 1 patent)

13. Flavie Pouillot (1 out of 7 patents)

14. Jérôme Bailly (1 out of 1 patent)

15. Emmanuelle-Cécile Dufour (1 out of 1 patent)

18 patents: Sort by Forward Citations

1. 12280080 - Antibacterial composition and uses thereof (2025-04-21),

2. 11957724 - Phage therapy ofinfections (2024-04-16),

3. 11458170 - Pharmaceutical composition comprising erythrocytes encapsulating a PLP-dependent enzyme and, a non-phosphate PLP precursor (2022-10-04),

4. 11273210 - Arginine deiminase encapsulated inside erythrocytes and their use in treating cancer and arginase-1 deficiency (2022-03-15),

5. 11141468 - Method of treating a mammal, including human, against cancer using methionine and asparagine depletion (2021-10-12),

6. 10780151 - Composition and therapeutic anti-tumour vaccine (2020-09-22),

7. 10780126 - Pharmaceutical kit comprising erythrocytes encapsulating a PLP-dependent enzyme and, a non-phosphate PLP precursor (2020-09-22),

8. 10286008 - Method for stabilising suspensions of red blood cells encapsulating an active ingredient (2019-05-14),

9. 10273444 - Lysis/resealing process and device for incorporating an active ingredient, in particular asparaginase or inositol hexaphosphate, in erythrocytes (2019-04-30),

10. 10046009 - Method of treatment using a pharmaceutical composition comprising erythrocytes encapsulating a PLP-dependent enzyme and its cofactor (2018-08-14),

11. 9968663 - Erythrocytes containing arginine deiminase (2018-05-15),

12. 9950049 - Composition and therapeutic anti-tumour vaccine (2018-04-24),

13. 9580739 - Test for predicting neutralization of asparaginase activity (2017-02-28),

14. 9364504 - Compostition and therapeutic anti-tumour vaccine (2016-06-14),

15. 9125876 - Erythrocytes containing arginine deiminase (2015-09-08),

ERYTECH Pharma is a clinical-stage biopharmaceutical company that specializes in developing innovative therapies for rare forms of cancer and orphan diseases. The company's core technology platform, ERYCAPS®, allows for the encapsulation of therapeutic substances within red blood cells, enabling targeted delivery and prolonged exposure of drugs to the affected cells. ERYTECH's product candidates target various types of cancer, including acute lymphoblastic leukemia, pancreatic cancer, and solid tumors. With a strong commitment to improving the lives of patients with limited treatment options, ERYTECH Pharma continues to advance its pipeline to provide new hope for those in need.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

18 Patents

#17 in Lyons

#1,072 in France

#33,187 in the World

Erytech Pharma

Forward Citations = 137

17 inventors:

Yann Godfrin (15 out of 17 patents)

Fabien Gay (4 out of 4 patents)

Vanessa Bourgeaux (4 out of 4 patents)

4. Thomas Cortese (3 out of 3 patents)

5. Alice Banz (3 out of 3 patents)

Please report any incorrect information to support@idiyas.com

Loading…